November 16, 2022

Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08

November 16, 2022

Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources

October 26, 2022

Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022

October 24, 2022

Myovant Sciences Cancels Second Quarter Earnings Conference Call

October 23, 2022

Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement

October 18, 2022

Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08

October 14, 2022

Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m. Eastern Time on October 26, 2022

October 2, 2022

Myovant Sciences Special Committee of Board Confirms Receipt of Preliminary, Non-binding Proposal from Sumitovant Biopharma and Sumitomo Pharma to Acquire Remaining Shares

September 16, 2022

Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08

September 16, 2022

Myovant Recognizes Prostate Cancer Awareness Month with Educational Sponsorships and Online Campaign to Encourage Patients to Speak Up, Seek Support and Be Informed